Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2024 1
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Top advances of the year: Bladder cancer.
Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, Chandran E, Simon N. Apolo AB, et al. Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. Cancer. 2025. PMID: 40782344 Review.
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug-delivery mechanisms in intravesical therapy for nonmuscle-invasive bladder cancer and muscle-invasive …
Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) …
Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder.
Cersosimo RJ. Cersosimo RJ. Am J Health Syst Pharm. 2024 Nov 7;81(22):1109-1123. doi: 10.1093/ajhp/zxae090. Am J Health Syst Pharm. 2024. PMID: 38679913 Review.
PURPOSE: The activity of targeted and immunotherapy for the management of advanced bladder cancer is reviewed. SUMMARY: Platinum-based chemotherapy is standard first-line treatment for advanced bladder cancer. ...Erdafitinib is indicated for advanced d …
PURPOSE: The activity of targeted and immunotherapy for the management of advanced bladder cancer is reviewed. SUMMARY: Platin …
Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.
Bracco FM, Wong CHM, Teoh JYC. Bracco FM, et al. Curr Opin Urol. 2025 Nov 1;35(6):653-660. doi: 10.1097/MOU.0000000000001330. Epub 2025 Aug 22. Curr Opin Urol. 2025. PMID: 40855943 Review.
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinoma, and their application in nonmuscle invasive bladder cancer (NMIBC) is an evolving frontier. This review is timely as it syn …
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinom …
Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.
Brown JR, Parikh M. Brown JR, et al. J Natl Compr Canc Netw. 2026 May;24(5):e267034. doi: 10.6004/jnccn.2026.7034. J Natl Compr Canc Netw. 2026. PMID: 42134402 Review.
Radical cystectomy has long been the standard of care for muscle-invasive bladder cancer (MIBC), an aggressive cancer with a high risk of progression to recurrent or metastatic disease. ...Two of these perioperative regimens-cisplatin/gemcitabin …
Radical cystectomy has long been the standard of care for muscle-invasive bladder cancer (MIBC), an aggre …
Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer.
Jang A, Grier AL, Sheng IY, Bari S, Barata PC, Garcia JA, Brown JR. Jang A, et al. Drugs Context. 2026 Jun 19;15:2025-9-1. doi: 10.7573/dic.2025-9-1. eCollection 2026. Drugs Context. 2026. PMID: 42367727 Free PMC article. Review.
Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. ...This review discusses how immune-checkpoint inhibitors (ICIs), which are drugs that empower your own immune system to fight cancer, are being in …
Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. ...This …
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates.
Yanagisawa T, Matsukawa A, Teoh JY, Mori K, Kawada T, Katayama S, Rajwa P, Quhal F, Pradere B, Moschini M, Shariat SF, Miki J, Kimura T. Yanagisawa T, et al. Bladder Cancer. 2025 Apr 25;11(2):23523735251335122. doi: 10.1177/23523735251335122. eCollection 2025 Apr-Jun. Bladder Cancer. 2025. PMID: 40296876 Free PMC article. Review.
CONTEXT: Several phase III randomized controlled trials (RCTs) have shown the importance of perioperative systemic therapy, especially for the efficacy of immune checkpoint inhibitors (ICIs) in both neoadjuvant and adjuvant settings for muscle-invasive bladder …
CONTEXT: Several phase III randomized controlled trials (RCTs) have shown the importance of perioperative systemic therapy, especially for t …
Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.
Meng L, Khorasanchi A, Jain R. Meng L, et al. Curr Treat Options Oncol. 2025 Nov;26(11):929-942. doi: 10.1007/s11864-025-01355-z. Epub 2025 Sep 26. Curr Treat Options Oncol. 2025. PMID: 41003886 Review.
The management of muscle-invasive bladder cancer (MIBC) is evolving rapidly, with the integration of neoadjuvant and adjuvant therapies and biomarker-driven patient selection now essential to refining treatment decisions. ...Immune checkpoint in …
The management of muscle-invasive bladder cancer (MIBC) is evolving rapidly, with the integration of neoa …
Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.
Petrelli F, Colombo Zefinetti L, D'Alessio A, Dottorini L, Ghidini A. Petrelli F, et al. Curr Oncol Rep. 2026 Jul 6;28(1):72. doi: 10.1007/s11912-026-01809-z. Curr Oncol Rep. 2026. PMID: 42406187 Review.
RECENT FINDINGS: In RCC, immune checkpoint inhibitor (ICI) plus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) doublets are established first-line standards, adjuvant pembrolizumab is the first agent to improve both disease-free and overall su …
RECENT FINDINGS: In RCC, immune checkpoint inhibitor (ICI) plus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibito …
Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025.
Ismaili N. Ismaili N. Front Endocrinol (Lausanne). 2026 Apr 1;17:1780259. doi: 10.3389/fendo.2026.1780259. eCollection 2026. Front Endocrinol (Lausanne). 2026. PMID: 41993992 Free PMC article.
RESULTS: Forty studies met inclusion criteria: bladder cancer (13), kidney cancer (9), prostate cancer (16), testicular cancer (1), and penile cancer (1). Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enf …
RESULTS: Forty studies met inclusion criteria: bladder cancer (13), kidney cancer (9), prostate cancer (16), testicular cancer …
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM. Mangold MH, et al. Int J Cancer. 2026 Apr 28. doi: 10.1002/ijc.70525. Online ahead of print. Int J Cancer. 2026. PMID: 42050770
For cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC), neoadjuvant cisplatin-based chemotherapy (NAC) is standard of care. More intensive regimens such as dose-dense methotrexate, vinblasti …
For cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy …
11 results